Progressive multiple sclerosis exhibits decreasing glutamate and glutamine over two years

In vivo evidence of glutamate toxicity in multiple sclerosis

(2014) Christina J. Azevedo et al.   ANNALS OF NEUROLOGY

Localisation of N-acetylaspartate in oligodendrocytes/myelin

(2013) Kaja Nordengen et al.   Brain Structure & Function

Clinical, MRI, and CSF Markers of Disability Progression in Multiple Sclerosis

(2013) Alberto Gajofatto et al.   DISEASE MARKERS

Effects of age and sex on the concentrations of glutamate and glutamine in the human brain

(2013) Sven Hädel et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Increased Concentrations of Glutamate and Glutamine in Normal-Appearing White Matter of Patients with Multiple Sclerosis and Normal MR Imaging Brain Scans

(2013) Anders Tisell et al.   PLoS One

Serial proton MR spectroscopy of gray and white matter in relapsing-remitting MS

(2012) I. I. Kirov et al.   NEUROLOGY

A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS

(2011) M. S. Freedman et al.   NEUROLOGY

A Longitudinal Proton Magnetic Resonance Spectroscopy Study of Mild Traumatic Brain Injury

(2010) Ronald A. Yeo et al.   JOURNAL OF NEUROTRAUMA

The link between inflammation, synaptic transmission and neurodegeneration in multiple sclerosis

(2009) D Centonze et al.   CELL DEATH AND DIFFERENTIATION

Proton Magnetic Resonance Spectroscopy in Multiple Sclerosis

(2008) Balasrinivasa R. Sajja et al.   NEUROIMAGING CLINICS OF NORTH AMERICA

Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study

(2007) B.R. Sajja et al.   Multiple Sclerosis Journal